Filing Details

Accession Number:
0000899243-16-029948
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-23 18:34:11
Reporting Period:
2016-09-21
Filing Date:
2016-09-23
Accepted Time:
2016-09-23 18:34:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1588538 Robert Ernest Paolantonio De C/O Biodelivery Sciences Intl, Inc.,
4131 Parklake Avenue, Suite 225
Raleigh NC 27612
Cfo, Secretary And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-21 1,483 $0.00 14,866 No 4 A Direct
Common Stock Acquisiton 2016-09-21 8,533 $0.00 23,399 No 4 M Direct
Common Stock Acquisiton 2016-09-21 34,392 $0.00 57,791 No 4 M Direct
Common Stock Disposition 2016-09-22 14,800 $2.44 42,991 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2016-09-21 8,533 $0.00 8,533 $0.00
Common Stock Restricted Stock Units Disposition 2016-09-21 34,392 $0.00 34,392 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
8,532 2016-02-22 2017-02-22 No 4 M Direct
68,783 2016-02-23 2018-02-23 No 4 M Direct
Footnotes
  1. The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016.
  2. The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017.
  3. The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018.
  4. The shares of common stock were sold under a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
  5. On September 22, 2016, the Reporting Person sold an aggregate of 14,800 shares of the Issuer's Common Stock at a weighted average price of $2.44 per share. The highest sale price for the Common Stock was $2.47 per share and the lowest sale price was $2.41 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.